TY - JOUR
T1 - Teriflunomide for the treatment of multiple sclerosis
AU - Warnke, Clemens
AU - Stüve, Olaf
AU - Kieseier, Bernd C.
N1 - Funding Information:
Dr Kieseier has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Genzyme/Sanofi Aventis, Grifols, Merck Serono, Mitsubishi Europe, Novartis, Roche, Talecris, and TEVA. Dr. Warnke and Dr. Stuve have nothing to declare.
PY - 2013/12
Y1 - 2013/12
N2 - Teriflunomide is a new active drug which has recently been approved as a first-line treatment of relapsing forms of MS in the US, Australia, Argentina, and the European Union. It is characterized by a once-daily oral application and a well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. Two phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS: efficacy was shown, with positive effects on relapse rates and disease progression for 14 mg/day. Overall, the safety profile in these studies was favorable. In patients treated with teriflunomide, the regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article, we review recent phase II and phase III clinical trial data, and discuss the potential of teriflunomide for the treatment of relapsing forms of MS.
AB - Teriflunomide is a new active drug which has recently been approved as a first-line treatment of relapsing forms of MS in the US, Australia, Argentina, and the European Union. It is characterized by a once-daily oral application and a well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. Two phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS: efficacy was shown, with positive effects on relapse rates and disease progression for 14 mg/day. Overall, the safety profile in these studies was favorable. In patients treated with teriflunomide, the regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article, we review recent phase II and phase III clinical trial data, and discuss the potential of teriflunomide for the treatment of relapsing forms of MS.
KW - Immunotherapy
KW - Multiple sclerosis
KW - Oral
KW - Teriflunomide
UR - http://www.scopus.com/inward/record.url?scp=84890054384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890054384&partnerID=8YFLogxK
U2 - 10.1016/j.clineuro.2013.09.030
DO - 10.1016/j.clineuro.2013.09.030
M3 - Article
C2 - 24321165
AN - SCOPUS:84890054384
SN - 0303-8467
VL - 115
SP - S90-S94
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
IS - SUPPL.1
ER -